An update on Nuvaton Bio's progress the past few months, as the company and stock have been performing well since receiving FDA approval of Taletrectinib, a drug for ROS1-positive non small cell lung cancer (NSCLC). Another drug in their pipeline NUV-1511 is in clinical studies for five indications.
Financial Statistics:
- $608 million cash
- Debt - minimal
- 341 million diluted shares outstanding
- 938 million market cap
Intellectual Property:
- Taletrectinib - Expected to expire from 2033 to 2042
- Safusidenib - Expected to expire from 2035 to 2041
- NUV-1511 - Expected to expire 2039 to 2043
Nuvation Bio's pipeline includes NUV-1511 a drug known as a DCC (drug-drug conjugate), which is in a phase 1/2 being tested for patients with advanced solid tumors in five separate indications here NUV-1511. This large study will include 466 patients to conclude in early 2027. The company expects more details forthcoming. Weekly chart below of Nuvation, thank you for reading.
No comments:
Post a Comment